December 21, 2016 / 9:58 PM / 8 months ago

BRIEF-Alexion's eculizumab fails second late stage trial

Dec 21 (Reuters) - Alexion Pharmaceuticals Inc -

* Alexion announces top-line results from phase 2/3 protect study of eculizumab (soliris) for the prevention of delayed graft function (DGF) after kidney transplantation

* Primary endpoint of incidence of DGF with a two-dose regimen of eculizumab compared with placebo did not reach statistical significance Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below